Skip to main content
OpenTrials
Completed

NCT Number: NCT04566861

Happy Mother - Healthy Baby: Supplement Study on Biological Processes Underlying Anxiety During Pregnancy

As a supplement to the ongoing randomized evaluation of the Cognitive Behavioral Therapy (CBT) anxiety prevention intervention in Pakistan (R01-MH111859), the investigators propose to explore potential biological mechanisms (related to inflammation and endocrine functioning) of antenatal anxiety through additional data collection with 300 pregnant women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Holy Family Hospital

Rawalpindi, Pakistan

About this study

This study will leverage the ongoing randomized evaluation of the CBT anxiety prevention intervention in Pakistan (R01-MH111859) to explore potential biological mechanisms. This CBT intervention targets both sub-threshold anxiety symptoms and generalized anxiety disorder (GAD) in early- to mid- pregnancy, aiming to both prevent and treat Common Mental Disorders (CMDs) (GAD and major depressive episodes (MDE)) as well as improve birth outcomes. The study team proposes to additionally study biological correlates of antenatal anxiety (i.e., immune and endocrine functioning) in 300 women: in addition to 200 drawn from our randomized trial (100 intervention, 100 usual care), the study will also include 100 healthy women without anxiety or depression. The aims are to 1) characterize the "immune phenotype" of anxious women across the peripartum, specifically by measuring the relation among anxiety symptoms and peripheral markers of inflammation within and across women (both anxious and healthy) and between those receiving the intervention and control; 2) determine the relation between levels of allopregnanolone (ALLO) in pregnancy and concurrent anxiety symptoms and future symptoms of postpartum depression (PPD), 3) examine the relation between changes in immune functioning and ALLO levels in anxious pregnancy across time, 4) examine whether immune function and/or ALLO are mediators or moderators of the association between antenatal anxiety and preterm birth and/or small-for-gestational age, and 5) examine the effects of both anxiety and the intervention (including biomarkers) on infant development at six weeks postpartum.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ability to understand spoken Urdu
  • pregnant, ≤22 weeks' gestation
  • age ≥18 years
  • residence ≤20 km of Holy Family Hospital
  • intent to reside in the study areas until the completion of the study

Exclusion criteria

  • Current anemia
  • Current major depressive episode (MDE on SCID) or life-threatening health conditions including e.g. active severe depression or suicidal ideation
  • Self-report of past or current significant learning disability
  • Self-report of past or current psychiatric disorder (e.g. bipolar disorder or schizophrenia) or psychiatric care (e.g. current use of anxiolytic drug and/or other psychotropic drug)
  • medical disorders or severe maternal morbidity that require inpatient management that would preclude participation (101)
  • ICU admission indicated by diagnosis (not only for assessment)

Treatment and study plan

Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy

Behavioral

Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.

Primary outcomes

  1. Peripheral Markers of Inflammation

    Time frame: trimester 1, trimester 2, trimester 3, 6 weeks postpartum

    Differences in levels of peripheral inflammatory markers and change in these markers across time (trimester 1 (T1), trimester 2 (T2), trimester 3 (T3) and postpartum (PP)) between anxious and healthy women, and between intervention and control women. Markers include IFNgamma, IL6, IL8, IL10, IL12p70, TNFalpha, IL17A, TARC, MIP1alpha, MCP4, Eotaxin

  2. Allopregnanolone Levels and Anxiety Symptoms Across the Peripartum

    Time frame: trimester 2, trimester 3, 6 weeks postpartum

    Measure differences in level of allopregnanolone (mean) at each time point and across time (trimester 1 (T1), trimester 2 (T2), trimester 3 (T3) and postpartum (PP)) between anxious women and healthy women, and between intervention and control.

    The results are measured by log-transformed values of the concentration of each cytokine in the plasma, in ng/mL (nanogram per milliliter).

  3. Allopregnanolone Levels Predicting Postpartum Depression

    Time frame: Trimester 2

    Differences in allopregnanolone levels at the second trimester between women who do and do not go on to develop postpartum depression (PPD).

    The results are measured by log-transformed values of the concentration of allopregnanolone in the plasma, in ng/ml (nanogram per milliliter.

    Women who have Allopregnanolone (ALLO) levels and developed PPD are analyzed.

  4. Allopregnanolone (ALLO) and Immune Function

    Time frame: trimester 2, trimester 3, 6 weeks postpartum

    Measure the relationship between ALLO levels and levels of peripheral inflammatory markers across time (trimester 2 (T2), trimester 3 (T3) and 6 weeks postpartum (W6))

Secondary outcomes

  1. Birth Outcomes

    Time frame: at birth

    Differences in birth outcomes (preterm birth, small for gestational age, low birth weight) between women with high inflammatory markers vs. those low in inflammatory markers, and also between anxious and healthy women.

  2. Infant Neuro-development Using Ages & Stages Questionnaire, Third Edition (ASQ-3)

    Time frame: 6 weeks postpartum

    Measure infant neuro-development using Ages & Stages Questionnaire to measure differences in infant neurodevelopment (communication, gross motor, fine motor, personal-social and problem solving) using a standardized questionnaire between those high in inflammatory markers vs. those low, and also between anxious and healthy women

    communication cut-off score 22.77 gross motor cut-off score 41.84 fine motor cut-off score 30.16 personal-social cut-off score 24.62 problem solving cut-off score 33.71

    Number of participants with impaired neuron-developmental infants (below cut-off scores) are reported below

Sponsors and collaborators

Lead sponsor

Johns Hopkins Bloomberg School of Public Health

Other

Collaborators

  • Human Development Research Foundation, Pakistan
  • National Institute of Mental Health (NIMH)
  • Rawalpindi Medical College, Pakistan
  • University of Liverpool

Registry information

Official study title

Biological Processes Underlying Anxiety During Pregnancy: A Substudy of an Anxiety-focused Early Prenatal Intervention for the Prevention of Common Mental Disorders in Pakistan

Acronym: HMHB-Bio

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Sep 28, 2020
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.